HLA-DR is a heterodimeric cell surface glycoprotein comprised of a 36 kD α (heavy) chain and a 27 kD b (light) chain. It is expressed on B cells, activated T cells, monocytes/macrophages, dendritic cells, and other non-professional APCs. In conjunction with the CD3/TCR complex and CD4 molecules, HLA-DR is critical for efficient peptide presentation to CD4+ T cells.
| Target |
HLA-DR |
| Reactivity |
Human, Monkey, Dog |
| Host |
Mouse |
| Clonality |
Monoclonal |
| Tested Applications |
FCM |
| Recommended dilutions |
FCM: 20 µl/1 million cells. Optimal dilutions/concentrations should be determined by the end user. |
| Immunogen |
Mononuclear cell leukemia acute undifferentiated. |
| Purification |
Affinity Chromatography |
| Form |
Liquid |
| Isotype |
IgG2a |
| Conjugation |
PerCP-Cy5.5 |
| Specificity |
B cells lymphocytes, Haemopoietic precursor cells, activated T-cells, monocytic cells and macrophages. This monoclonal antibody is validated in Nalm-6 cell line |
| Storage |
Aliquot and store in the dark at 2°C to 8°C. Avoid exposure to light. |
| Molecular Weight |
36 kDa |
| Swiss Prot |
P04233
|
| GeneID |
3122
|
| Buffer |
The reagent is provided in aqueous buffered solution containing protein stabilizer, and ≤0.09% sodium Azide |
| UNSPSC Code |
12352203 |
| Availability |
Shipped within 2-3 weeks. |
| Note |
This product is for research use only. |